No Evidence Supporting Citicoline Use During Prolonged Cardiopulmonary Bypass
Citicoline is not recommended for patients undergoing prolonged cardiopulmonary bypass (>120 minutes) as there is no guideline support or high-quality evidence demonstrating benefit for mortality, morbidity, or quality of life in this specific clinical context.
Evidence Analysis
Guideline Recommendations for Prolonged CPB
The most recent 2024 EACTS/EACTAIC/EBCP guidelines 1 and 2019 guidelines 2 provide comprehensive recommendations for managing prolonged CPB but make no mention of citicoline or neuroprotective pharmacologic agents for this indication. Instead, the guidelines focus on:
- Goal-directed perfusion (GDP) is recommended (Class I, Level A) to reduce acute kidney injury, with DO₂ maintained between 280-300 ml/min/m² during normothermic CPB 1
- Pulsatile perfusion should be considered (Class IIa, Level B) to improve renal perfusion and reduce postoperative injury, especially in high-risk patients 1
- MAP management between 50-80 mmHg is recommended, with individualization based on preoperative values 2
Citicoline Evidence Review
The single research study addressing citicoline in cardiac surgery 3 examined 104 patients undergoing cardiac procedures with CPB. While this study showed improved neurocognitive outcomes (MoCA scores) and sleep architecture stabilization in the citicoline group, it has critical limitations:
- Does not specifically address prolonged CPB (>120 minutes)
- Published in a lower-tier journal (Georgian Medical News)
- Small sample size (52 per group)
- Primary outcomes were neurocognitive function and polysomnography—not mortality, major morbidity, or quality of life
- No guideline bodies have incorporated these findings into recommendations
The other citicoline study 4 examined memory function in healthy older adults—completely irrelevant to the cardiac surgery population.
FDA Drug Label
The FDA labeling for citicoline 5 indicates use for "relief of pressure, bloating, and fullness commonly referred to as gas"—this appears to be a labeling error or different formulation and provides no support for perioperative cardiac surgery use.
Clinical Approach to Prolonged CPB
Instead of citicoline, focus on evidence-based strategies:
Optimize oxygen delivery: Maintain DO₂ >280-300 ml/min/m² through pump flow adjustment based on hemoglobin content 1
Consider pulsatile flow: Particularly in high-risk patients (elderly, pre-existing renal dysfunction, diabetes) 1
Maintain adequate MAP: Target 50-80 mmHg, individualized to preoperative baseline; avoid forcing MAP >80 mmHg with vasopressors (Class III recommendation) 2
Transfusion thresholds: Transfuse PRBCs if hematocrit <18% (Hgb 6.0 g/dL); consider between 18-24% based on DO₂ adequacy 1
Avoid routine corticosteroids: Large RCTs (DECS and SIRS trials) showed no mortality or morbidity benefit 2
Critical Caveats
- Prolonged CPB increases risk of vasodilation, inflammatory response, and end-organ injury through mechanisms unaddressed by citicoline
- The 2019 and 2024 guidelines [1-2,6,7] represent consensus from major European societies (EACTS, EACTA, EBCP) and make no recommendation for neuroprotective pharmacotherapy
- No alternative anticoagulation relevance: Citicoline is not mentioned in comprehensive anticoagulation guidelines for CPB 7
The absence of citicoline from all major CPB guidelines, combined with lack of high-quality evidence for mortality/morbidity benefit in prolonged bypass, makes its use unsupported in current evidence-based practice.